Voyager Therapeutics (VYGR)
(Delayed Data from NSDQ)
$8.77 USD
-0.17 (-1.90%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $8.77 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Price, Consensus and EPS Surprise
VYGR 8.77 -0.17(-1.90%)
Will VYGR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VYGR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VYGR
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
VYGR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat
Other News for VYGR
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VYGR Makes Notable Cross Below Critical Moving Average
Voyager Therapeutics to Present at Multiple Virtual Investor Conferences
Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer
Voyager Therapeutics Welcomes New CFO Nathan Jorgensen